| Log in

Glenmark Pharmaceuticals may raise up to $300M

30 October, 2014

Mumbai-based Glenmark Pharmaceuticals Limited, which focuses on research to develop new chemical entities (NCEs) and new biological entities (NBEs), is looking to raise as much as $300 million (over Rs 1,800 crore) through insurance of securities in one or more tranches, as per a stock market disclosure.

The firm did not disclose the purpose of the proposed fundraising.

Glenmark has also sought to increase the investment limits of Foreign Institution Investors (FIIs) from 40 per cent to 55 per cent. It will seek shareholders approval for the same.

(Edited by Joby Puthuparampil Johnson)


Leave Your Comment
Glenmark Pharma launches manufacturing facility in Switzerland

Glenmark Pharma launches manufacturing facility in Switzerland

TEAM VCC 3 years ago
Mumbai-based Glenmark Pharmaceutical Limited, which focuses on research to...
Temasek to invest $151M in Glenmark Pharma

Temasek to invest $151M in Glenmark Pharma

TEAM VCC 3 years ago
Glenmark Pharmaceuticals Ltd is raising Rs 945 crore ($151 million) through a...
Glenmark gets USFDA approval for skin infection cream

Glenmark gets USFDA approval for skin infection cream

Jasleen Kaur Batra 3 years ago
Mumbai-based Glenmark Pharmaceutical Limited, which focuses on research to...
No Comments

Glenmark Pharmaceuticals may raise up to $300M

Powered by WordPress.com VIP